Copyright
©The Author(s) 2018.
World J Clin Oncol. Apr 10, 2018; 9(2): 33-41
Published online Apr 10, 2018. doi: 10.5306/wjco.v9.i2.33
Published online Apr 10, 2018. doi: 10.5306/wjco.v9.i2.33
Figure 1 Overall survival regarding tumor-infiltrating lymphocytes (cut-off: 50%) for Luminal A (A), Luminal B (B), HER2-enriched (C) and Triple Negative group (D).
- Citation: Galvez M, Castaneda CA, Sanchez J, Castillo M, Rebaza LP, Calderon G, Cruz MDL, Cotrina JM, Abugattas J, Dunstan J, Guerra H, Mejia O, Gomez HL. Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. World J Clin Oncol 2018; 9(2): 33-41
- URL: https://www.wjgnet.com/2218-4333/full/v9/i2/33.htm
- DOI: https://dx.doi.org/10.5306/wjco.v9.i2.33